PHASE III STUDY FOR SEVERE SEPSIS TREATMENT ERITORAN (E5564) DOES NOT MEET PRIMARY ENDPOINT

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today, based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, that it will not submit marketing authorization applications for the severe sepsis treatment eritoran (generic name; E5564) to regulatory authorities in the United States, European Union (EU) and Japan by the end of fiscal year 2010 (year ending March 31, 2011), as previously planned. The decision was based on the fact that the trial, a Phase III study conducted in patients with severe sepsis, did not meet its primary endpoint of 28-day all-cause mortality. The company will continue its analysis of the eritoran clinical trial data and determine next steps.

[Notes to editors]

1. About the ACCESS Trial